pmc logo image
Logo of postmedjPostgraduate Medical JournalCurrent TOCInstructions for authors

Formats:

Postgrad Med J. 1998 June; 74(872): 321–326.
PMCID: PMC2360956
Neurocysticercosis.
R. K. Garg
Division of Neurology, Banaras Hindu University, Varanasi, India.
Abstract
Neurocysticercosis is the most common parasitic disease of the central nervous system. Varied clinical manifestations occur, due to deposition of larvae of the parasite Taenia solium in cerebral parenchyma, meninges, spinal cord, muscles, eyes and skin. The diagnosis of neurocysticercosis can be made with a fairly high degree of accuracy with the help of computed tomography and magnetic resonance imaging. Serological tests and histopathological examination of subcutaneous nodules provide additional support in establishing the diagnosis. The anticysticercal drugs albendazole and praziquantel have been extensively used, and found to be effective for all types of neurocysticercosis. However, recently controversy has been raised about their safety, and long-term clinical usefulness. Preventive health measures, such as provision of safe drinking water and excretion disposal, still offer the best ways to manage this disease.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Del Brutto OH, Sotelo J. Neurocysticercosis: an update. Rev Infect Dis. 1988 Nov–Dec;10(6):1075–1087. [PubMed]
  • Brown WJ, Voge M. Cysticercosis. A modern day plague. Pediatr Clin North Am. 1985 Aug;32(4):953–969. [PubMed]
  • Webbe G. Human cysticercosis: parasitology, pathology, clinical manifestations and available treatment. Pharmacol Ther. 1994 Oct;64(1):175–200. [PubMed]
  • Cook GC. Neurocysticercosis: parasitology, clinical presentation, diagnosis, and recent advances in management. Q J Med. 1988 Aug;68(256):575–583. [PubMed]
  • Wadia N, Desai S, Bhatt M. Disseminated cysticercosis. New observations, including CT scan findings and experience with treatment by praziquantel. Brain. 1988 Jun;111 (:597–614. [PubMed]
  • Del Brutto OH. Cysticercosis and cerebrovascular disease: a review. J Neurol Neurosurg Psychiatry. 1992 Apr;55(4):252–254. [PMC free article] [PubMed]
  • Alarcón F, Vanormelingen K, Moncayo J, Viñán I. Cerebral cysticercosis as a risk factor for stroke in young and middle-aged people. Stroke. 1992 Nov;23(11):1563–1565. [PubMed]
  • Isidro-Llorens A, Dachs F, Vidal J, Sarrias M. Spinal cysticercosis. Case report and review. Paraplegia. 1993 Feb;31(2):128–130. [PubMed]
  • Rodríguez-Carbajal J, Boleaga-Duran B, Dorfsman J. The role of computed tomography (CT) in the diagnosis of neurocysticercosis. Childs Nerv Syst. 1987;3(4):199–202. [PubMed]
  • McCormick GF, Zee CS, Heiden J. Cysticercosis cerebri. Review of 127 cases. Arch Neurol. 1982 Sep;39(9):534–539. [PubMed]
  • Kramer LD, Locke GE, Byrd SE, Daryabagi J. Cerebral cysticercosis: documentation of natural history with CT. Radiology. 1989 May;171(2):459–462. [PubMed]
  • Carpio A, Placencia M, Santillán F, Escobar A. A proposal for classification of neurocysticercosis. Can J Neurol Sci. 1994 Feb;21(1):43–47. [PubMed]
  • Del Brutto OH, Guevara J, Sotelo J. Intrasellar cysticercosis. J Neurosurg. 1988 Jul;69(1):58–60. [PubMed]
  • Martinez HR, Rangel-Guerra R, Elizondo G, Gonzalez J, Todd LE, Ancer J, Prakash SS. MR imaging in neurocysticercosis: a study of 56 cases. AJNR Am J Neuroradiol. 1989 Sep–Oct;10(5):1011–1019. [PubMed]
  • Tsang VC, Brand JA, Boyer AE. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis. 1989 Jan;159(1):50–59. [PubMed]
  • Wilson M, Bryan RT, Fried JA, Ware DA, Schantz PM, Pilcher JB, Tsang VC. Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis. 1991 Nov;164(5):1007–1009. [PubMed]
  • Rosas N, Sotelo J, Nieto D. ELISA in the diagnosis of neurocysticercosis. Arch Neurol. 1986 Apr;43(4):353–356. [PubMed]
  • Plancarte A, Espinoza B, Flisser A. Immunodiagnosis of human neurocysticercosis by enzyme-linked immunosorbent assay. Childs Nerv Syst. 1987;3(4):203–205. [PubMed]
  • Arora VK, Gupta K, Singh N, Bhatia A. Cytomorphologic panorama of cysticercosis on fine needle aspiration. A review of 298 cases. Acta Cytol. 1994 May–Jun;38(3):377–380. [PubMed]
  • Sotelo J, Escobedo F, Rodriguez-Carbajal J, Torres B, Rubio-Donnadieu F. Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med. 1984 Apr 19;310(16):1001–1007. [PubMed]
  • Del Brutto OH, Sotelo J, Roman GC. Therapy for neurocysticercosis: a reappraisal. Clin Infect Dis. 1993 Oct;17(4):730–735. [PubMed]
  • Escobedo F, Penagos P, Rodriguez J, Sotelo J. Albendazole therapy for neurocysticercosis. Arch Intern Med. 1987 Apr;147(4):738–741. [PubMed]
  • Del Brutto OH, Sotelo J, Aguirre R, Díaz-Calderón E, Alarcón TA. Albendazole therapy for giant subarachnoid cysticerci. Arch Neurol. 1992 May;49(5):535–538. [PubMed]
  • Del Brutto OH, Sotelo J, Aguirre R, Díaz-Calderón E, Alarcón TA. Albendazole therapy for giant subarachnoid cysticerci. Arch Neurol. 1992 May;49(5):535–538. [PubMed]
  • Martinez HR, Rangel-Guerra R, Arredondo-Estrada JH, Marfil A, Onofre J. Medical and surgical treatment in neurocysticercosis a magnetic resonance study of 161 cases. J Neurol Sci. 1995 May;130(1):25–34. [PubMed]
  • Cruz I, Cruz ME, Carrasco F, Horton J. Neurocysticercosis: optimal dose treatment with albendazole. J Neurol Sci. 1995 Nov;133(1-2):152–154. [PubMed]
  • Woo E, Yu YL, Huang CY. Cerebral infarct precipitated by praziquantel in neurocysticercosis--a cautionary note. Trop Geogr Med. 1988 Apr;40(2):143–146. [PubMed]
  • Couldwell WT, Zee CS, Apuzzo ML. Definition of the role of contemporary surgical management in cisternal and parenchymatous cysticercosis cerebri. Neurosurgery. 1991 Feb;28(2):231–237. [PubMed]
  • Mitchell WG, Crawford TO. Intraparenchymal cerebral cysticercosis in children: diagnosis and treatment. Pediatrics. 1988 Jul;82(1):76–82. [PubMed]
  • Padma MV, Behari M, Misra NK, Ahuja GK. Albendazole in neurocysticercosis. Natl Med J India. 1995 Nov–Dec;8(6):255–258. [PubMed]
  • Kramer LD. Medical treatment of cysticercosis--ineffective. Arch Neurol. 1995 Jan;52(1):101–102. [PubMed]
  • Carpio A, Santillán F, León P, Flores C, Hauser WA. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med. 1995 Oct 9;155(18):1982–1988. [PubMed]
  • Wadia RS, Makhale CN, Kelkar AV, Grant KB. Focal epilepsy in India with special reference to lesions showing ring or disc-like enhancement on contrast computed tomography. J Neurol Neurosurg Psychiatry. 1987 Oct;50(10):1298–1301. [PMC free article] [PubMed]
  • Rajshekhar V, Haran RP, Prakash GS, Chandy MJ. Differentiating solitary small cysticercus granulomas and tuberculomas in patients with epilepsy. Clinical and computerized tomographic criteria. J Neurosurg. 1993 Mar;78(3):402–407. [PubMed]
  • Rajshekhar V. Albendazole therapy for persistent, solitary cysticercus granulomas in patients with seizures. Neurology. 1993 Jun;43(6):1238–1240. [PubMed]
  • Padma MV, Behari M, Misra NK, Ahuja GK. Albendazole in single CT ring lesions in epilepsy. Neurology. 1994 Jul;44(7):1344–1346. [PubMed]
  • Del Brutto OH, Santibañez R, Noboa CA, Aguirre R, Díaz E, Alarcón TA. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology. 1992 Feb;42(2):389–392. [PubMed]
  • Vazquez V, Sotelo J. The course of seizures after treatment for cerebral cysticercosis. N Engl J Med. 1992 Sep 3;327(10):696–701. [PubMed]
  • Del Brutto OH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology. 1994 Sep;44(9):1706–1709. [PubMed]